Tilray Brands stock extended its sell-off this week, sinking to a record low as concerns about the company intensified. The shares fell to $2.34, leaving them down 74% so far this year, 55% over the past six months, and 98% over the past five years. That makes Tilray one of Wall Street’s biggest laggards. The question now is whether this crash presents a buying opportunity.
Tilray Brands has fallen as cannabis rescheduling process stalls
TLRY stock has been in a strong sell-off, mirroring the performance of other companies in the cannabis industry. The AdvisorShares Pure US Cannabis ETF (MSOS) has slumped by 16% in the last six months and 23% this year.
Similarly, companies like Curaleaf, Truelieve, Green Thumb Industries, and Verano Holdings have all dropped by double digits this year.
These stocks have plunged as the cannabis rescheduling process that President Donald Trump started in April stalls. In that month, the Justice Department moved marijuana covered by state medical licenses from Schedule 1 to Schedule III. Adult-use cannabis remained in Schedule 1.
At the same time, a separate DEA hearing moved all cannabis to Schedule III, with hearings continuing to date. Also, several lawsuits have been filed challenging the hearings and the rescheduling as a whole.
As such, while industry players are optimistic that the rescheduling will go on well, there are also concerns about the pace.
On the positive side, Democrats won the midterm elections by a large margin. They now control the Senate by about 56 seats and the House of Representatives by over 250 seats. As such, the Senate likely has the votes it needs to pass the SAFE Banking Act, which will make it easy for cannabis companies to access banking services.
READ MORE: Tilray Brands stock analysis ahead of earnings: will it rebound or fall further?
Tilray Brands is not active in the United States but the management has said that it will do so once there is regulatory clarity. Such a move would let it use its experience in Canada and other countries to expand in the country.
Tilray Brands’ business is growing
Despite the ongoing weakness in Tilray Brands’ stock, there are signs that the company’s business is doing well. The last earnings report showed that its net revenue rose by 23% to $257 million, with its gross profit hitting $77.5 million.
Most of its businesses grew during the quarter. Its beverage revenue jumped by 82% to $101.5 million, making it the biggest part of its business. This growth was driven by its recent acquisitions, including BrewDog.
The distribution business made over $84.3 million, up by 14%, while its wellness segment made $15.3 million. These metrics were offset by its cannabis business, which made $56.1 million, down from $64 million in the same period last year. The company also made a net loss of over $40 million.
TLRY stock price technical analysis
Tilray Brands stock chart | Source: TradingView
The daily chart shows that the Tilray Brands stock has been in a strong sell-off this year. The sell-off accelerated after the stock hit a crucial resistance level of $4.96 in August this year.
It has remained below the 50-day Exponential Moving Average (EMA), a sign that bears have prevailed. Also, the stock has slumped below the Supertrend indicator.
The Relative Strength Index (RSI) has also dropped to the oversold level of 30. Therefore, the path of the least resistance for the stock is downwards, with the next level to watch being at $2.0. A drop below that level will point to more downside, potentially to $1.50.
However, it is worth noting that Tilray Brands stock tends to have some short squeezes, especially when there is cannabis regulation news.
The post Tilray Brands stock has crashed to a record low: is this fallen angel a buy? appeared first on Invezz
